In NSCLC, the suppression of METTL3 can enhance the sensitivity of tumor-bearing mice to anti-PD-1 treatment, and patients with NSCLC exhibiting low METTL3 expression have a more favorable prognosis with immunotherapy (122). Here, PDCD1 is linked to neoplasm.